Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.